Personalized Medicine News and Research

RSS

EU-funded 4DCellFate project to kick off today

Today European scientists are meeting to kick off the 4DCellFate project, funded by the European Commission under the FP7 program.

13 Feb 2012

Road Hockey To Conquer Cancer to raise funding for personalized medicine

After an extraordinary inaugural event in 2011 that raised $2.4 million for cancer research at The Princess Margaret Cancer Centre and Canadian Cancer Society, Road Hockey To Conquer Cancer kicked off its sophomore campaign with a flash-mob road hockey game on February 7 at 12:30pm in the courtyard at Commerce Court.

9 Feb 2012

Sanford-Burnham, Florida Hospital and Moffitt partner to develop PMP Florida

Moffitt Cancer Center, Sanford-Burnham Medical Research Institute and Florida Hospital have announced they will collaborate on the creation of a Personalized Medicine Partnership of Florida (PMP Florida). The partnership will conduct collaborative research to accelerate discovery and develop new treatments in the areas of cancer and metabolic diseases, including obesity, diabetes and cardiovascular disease.

9 Feb 2012

Ethical framework to guide coverage and reimbursement decisions for expensive orphan drugs

How can insurers justify spending hundreds of thousands of dollars per patient per year on "orphan drugs" - extremely expensive medications for rare conditions that are mostly chronic and life-threatening -- when this money could provide greater overall health benefit if spread out among many other patients?

8 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Roche’s new breast cancer drug Pertuzumab up for FDA review

U.S. health regulators, the Food and Drugs Administration (FDA) has granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. Pertuzumab approval decision is due by June 8th this year. It could be used with Herceptin in HER2-positive patients. This was announced by Roche Holding AG's Genentech unit on Tuesday.

7 Feb 2012

Vending machine to dispense “morning after pills” at college sparks debate

Now students at Shippensburg University in Pennsylvania can get the “morning after” pill by sliding $25 into a vending machine, an idea that has drawn the attention of federal regulators and raised questions about how accessible emergency contraception should be.

7 Feb 2012

TGen to host Pediatric Cancer Translational Genomics in Scottsdale

The Translational Genomics Research Institute (TGen) will host Pediatric Cancer Translational Genomics Feb. 6-8 at the Hotel Valley Ho in Scottsdale, bringing together more than 150 leading pediatric cancer researchers, clinicians and foundations to promote the exchange of information and ideas for advancing pediatric cancer research and treatment.

7 Feb 2012

Whole exome sequencing provides clues about rare mutations in aneurysms

An innovative approach to genome screening has provided clues about rare mutations that may make people susceptible to brain aneurysms, predisposing them to brain bleeds, according to preliminary late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

4 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

Scientists establish HCV infection in liver-like cells derived from iPSCs

Hepatitis C, an infectious disease that can cause inflammation and organ failure, has different effects on different people. But no one is sure why some people are very susceptible to the infection, while others are resistant. Scientists believe that if they could study liver cells from different people in the lab, they could determine how genetic differences produce these varying responses. However, liver cells are difficult to obtain and notoriously difficult to grow in a lab dish because they tend to lose their normal structure and function when removed from the body.

2 Feb 2012

Canadian Government announces investment in personalized medicine

The Harper Government today announced an important investment that will help Canadians in getting more effective treatments and make the healthcare system more sustainable through personalized medicine.

1 Feb 2012

Researchers use liquid laser to diagnose genetic mutations linked with cancer

Using a liquid laser, University of Michigan researchers have developed a better way to detect the slight genetic mutations that might predispose a person to a particular type of cancer or other diseases.

1 Feb 2012

Dana-Farber receives MLSC grant to expand cancer imaging research

The Massachusetts Life Sciences Center has awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Researchers identify two genetic mutations responsible for brain cancer in children

An international research team led by the Research Institute of the McGill University Health Centre (RI MUHC) has made a major genetic breakthrough that could change the way pediatric cancers are treated in the future.

30 Jan 2012

Everist Genomics' CardioDefender Device to be featured at Wearable Technologies Conference

Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.

30 Jan 2012

Lab21 acquires new real time PCR technology

Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.

23 Jan 2012

WSU professors receive NSF grant to develop math model of liver metabolism

Predicting problems in one of the body's most complex organs soon may become easier because of work being done by Wayne State University researchers.

20 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012